IDIBELL on the media
Researchers identify a possible therapy against Rendu-Osler disease
Research It is a rare disease that causes malformations in blood vessels. The study has discovered the implication of a protein in the development of the pathology.
Isabel Fabregat receives a grant from the Ramón Areces Foundation to study liver fibrosis
The Ramón Areces Foundation has awarded Grants for Research in Life Sciences and Matter corresponding to its 20th edition. In intercellular dialogue and interactome area, Dr. Isabel Fabregat, head of the research group “TGF-beta and cancer” at IDIBELL, in collaboration with Drs. Aránzazu Sánchez and Blanca Herrera from the Complutense University of Madrid, have received one of the grants.
60% of Covid-19 patients develop neurological symptoms
60% of Covid-19 inpatients develop neurological symptoms and 12% of post-Covid patients have neurological sequelae.
Saturday was the day to enjoy and experiment in the Hospitalet science park
This year within the framework of the Hospitalet Spring Festival, we enjoyed again in the Science Park.
We launch VacunAcció: a project to immunize against fake news
IDIBELL and the Virolai school, together in a new educational initiative of the Escolab program of the Barcelona City Council
IDIBELL and Bellvitge Hospital lead a study on the effectiveness of icatibant against COVID-19
Bellvitge Biomedical Research Institute (IDIBELL) and Bellvitge University Hospital had launched a clinical study, along with the pharmaceutical company Takeda, to evaluate the efficacy and safety of Icatibant as a treatment against COVID-19.
Identified the genetic mechanisms for the acquisition of resistance to antibiotics in H. parainfluenzae
The work of the Epidemiology of Bacterial Infections research group of IDIBELL and HUB indicates that the bacteria could achieve the resistance through the acquisition of mobile DNA fragments.
IDIBELL celebrates the Kickoff Meeting on Health Research Projects awarded by ISCIII
Last Tuesday, April 20th, within the Areté Training Program, the IDIBELL AES-2020 Kick Off Meeting was held, aimed at all researchers who have obtained a health research project within the “2020 AES Call” funded by the ISCIII.
Confirmed the presence of autoantibodies against type 1 interferon as an indicator of COVID-19 poor prognosis
A study led by IDIBELL and the Infanta Eleonor University Hospital in Madrid shows that 10% of patients with severe COVID-19 present neutralizing antibodies against the cytokine interferon type 1.
